The case in front of me: 2.4 mg · liraglutide.
I want to know whether this is a real physical effect or an artefact of how it is measured.
What prompted the question is an inconsistency between two sources I otherwise trust.
What is the causal chain, and where does it stop being established?
Two administrations of 1.2 mg instead of one of 2.4 mg — the same 2.4 mg a week either way. Total weekly exposure is unchanged; what changes is the peak-to-trough ratio, and for an agent with a half-life measured in days the trough barely moves because the dosing interval is already short relative to it. The arithmetic is the easy part: 2.4 ÷ 2 = 1.2. Whether it is worth doing is a pharmacokinetic question, and nothing here is medical advice.
The part that matters: this is one of the questions where the pharmacokinetics gives a clean answer and the anecdotal reports disagree with it.
Splitting that same weekly dose into two half-doses at 3.5-day intervals gives τ/t½ = 0.5 and a peak-to-trough ratio of about 1.41. The profile is flatter, and the difference between a 2-fold and a 1.4-fold swing is not obviously perceptible.
| Vial | Diluent | Concentration | 0.25 mg | 0.5 mg | 1 mg | 2.5 mg |
|---|---|---|---|---|---|---|
| 5 mg | 1 mL | 5 mg/mL | 5 u | 10 u | 20 u | 50 u |
| 5 mg | 2 mL | 2.5 mg/mL | 10 u | 20 u | 40 u | 100 u |
| 10 mg | 1 mL | 10 mg/mL | 2.5 u | 5 u | 10 u | 25 u |
| 10 mg | 2 mL | 5 mg/mL | 5 u | 10 u | 20 u | 50 u |
| 10 mg | 3 mL | 3.33 mg/mL | 7.5 u | 15 u | 30 u | 75 u |
Units are U-100 insulin units, where 1 unit = 0.01 mL. Divide dose by concentration for millilitres, then multiply by 100.
Specifically, reported tolerability improvements with splitting may reflect the smaller absolute amount arriving at once rather than the exposure profile, which is a different mechanism and is not well characterised.
Published half-lives for the agents in this class range from about thirteen hours to about a week, which is the range over which the answer changes.
For a weekly half-life, weekly dosing is already flat. Splitting buys very little.
edited 28 Dec 2025 by tenth_of_a_unit — fixed an arithmetic slip in the third paragraph
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsMechanically, every split doubles the number of stopper entries and injections, which is a real cost against an uncertain benefit.
Accumulation to steady state takes four to five half-lives regardless of how the dose is divided. Splitting does not shorten it and does not change the average exposure.
Halving a dose accurately requires the reading resolution to support it. A 10-unit dose split into two 5-unit doses is at the coarse end of any barrel.
The peak-to-trough relationship 2^(τ/t½) is standard pharmacokinetics for a one-compartment model with first-order elimination and is the correct tool for this question.
Nothing here is medical advice, and research-use compounds are not approved for human use.
Work out 2^(τ/t½) for your agent before arguing about this. It usually settles it.
Answer first: splitting a weekly dose into smaller more frequent doses reduces peak-to-trough variation, and whether that helps depends entirely on the half-life of the agent.
For a drug with elimination half-life t½ dosed at interval τ, the peak-to-trough ratio at steady state is 2^(τ/t½). With a one-week half-life dosed weekly, τ/t½ = 1, so the ratio is 2 — a factor of two between peak and trough, which is already flat by pharmacological standards.
Specifically, a slower titration achieves a lower peak exposure with fewer handling steps, which is why it is the better-evidenced answer to the same problem.
No trial in this class has evaluated a split schedule against the licensed one, so any comparison is anecdotal.
Halving a dose you cannot read accurately introduces an error larger than the effect you are chasing.
Every split is another stopper entry. Count that cost.
The short version: pharmacokinetically defensible for shorter half-lives, close to pointless for the weekly agents, and it multiplies handling opportunities either way.
For a thirteen-hour half-life agent dosed daily, τ/t½ is about 1.8 and the swing is nearly fourfold, which is why the daily agents feel peakier and why splitting them would have more effect.
Titration schedules in the trial programmes were designed to manage gastrointestinal tolerability and are the evidenced approach to that problem.
If you cannot read half the dose accurately, you cannot split it accurately.
Start with the half-life. For an agent with a one-week half-life, weekly dosing already produces a nearly flat profile and splitting changes very little.
Each additional injection is an additional stopper entry, an additional needle and an additional opportunity to introduce contamination into a preparation that has no release testing behind it.
More injections means more handling risk, and that cost is certain while the benefit is not.
Slower titration has evidence; splitting has anecdote. Prefer the first.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.